Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Plant-based vegetarian and vegan diets may have the lowest carbon footprint in the United States, but new data analysis shows fish-based pescatarian diets are the best.
Read Full NewsResearch reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.
The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.
Intellia’s trial for nex-z in ATTR-CM remains under clinical hold.
Arai breaks down key recommendations from the 2025 AGA gastroparesis guidelines and what they mean for the field at large.
IMMpactful: Risankizumab Shows Greater Clinical Response to Deucravacitinib in Psoriasis
1.
More men with prostate cancer are avoiding unnecessary surgery
2.
Pirtobrutinib May Be Beneficial in Follicular Lymphoma with Severe Pretreatment.
3.
How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace
4.
What is Mohs micrographic surgery? 8 FAQs about Mohs
5.
Guidelines for cervical cancer screening and the risk of preterm birth in young women.
1.
Next-Generation Sequencing in Oncology: Unlocking the Future of Precision Medicine
2.
Understanding the HAS-BLED Score: What It Is and Why It Matters
3.
Seeing Beyond the Pink Ribbon: AI's New Battle Against Breast Cancer
4.
Hematologic Cytomorphology: From Microscopy to Molecular Diagnostics
5.
Unlocking the Potential of Trabectedin: A Novel Therapy for Cancer Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
2.
Efficient Management of First line ALK-rearranged NSCLC - Part III
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
4.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge